Artículos de interés en tuberculosis

Comparison of screening strategies to improve the diagnosis of latent tuberculosis infection in the HIVpositive population: a cohort study
Katrina M Pollock, Herman Tam, Lisa Grass, Sharleen Bowes, Graham S Cooke, Manish Pareek, Damien Montamat-Sicotte, Moses Kapembwa, Graham P Taylor, Ajit Lalvani
BMJ Open 2012;2:e000762. doi:10.1136/bmjopen-2011-000762

Evolución y tratamiento de pacientes con tuberculosis multirresistente
Marta Ramírez Lapausa, José Francisco Pascual Pareja, Mariam Amer Pérez, José Luis Vidal Pérez y Arturo Noguerado Asensio
IdiPAZ, Servicio de Medicina Interna, Unidad de Aislamiento, Hospital Universitario de Cantoblanco, La Paz, Madrid, España
M. Ramírez Lapausa et al / Med Clin (Barc). 2012;138(15):643–649

¿Un nuevo esquema de quimioprofilaxis en tuberculosis?
Domingo Palmero
Jefe División Neumotisiología, Hospital Dr. F. J. Muñiz;
Presidente rGLC-Américas-OPS/OMS.
Revista Americana de Medicina Respiratoria Vol 12 Nº 1 - Marzo 2012

National Survey of Drug-Resistant Tuberculosis in China
Yanlin Zhao, Ph.D., Shaofa Xu, M.D., Lixia Wang, M.S., Daniel P. Chin, M.D., Shengfen Wang, Ph.D., Guanglu Jiang, B.S., Hui Xia, M.S., Yang Zhou, M.S., Qiang Li, M.S., Xichao Ou, M.S., Yu Pang, Ph.D., Yuanyuan Song, B.S., Bing Zhao, B.S., Hongtao Zhang, Ph.D., Guangxue He, B.S., Jing Guo, Ph.D., and Yu Wang, M.D.
N Engl J Med 2012;366:2161-70.

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler, M.D., Vija Skripconoka, M.D., Epifanio Sanchez-Garavito, M.D., Heping Xiao, M.D., Jose L. Cabrera-Rivero, M.D., Dante E. Vargas-Vasquez, M.D., Mengqiu Gao, M.D., Ph.D., Mohamed Awad, M.B., B.Ch., M.D., Seung-Kyu Park, M.D., Ph.D., Tae Sun Shim, M.D., Ph.D., Gee Young Suh, M.D., Manfred Danilovits, M.D., Hideo Ogata, M.D., Anu Kurve, M.D., Joon Chang, M.D., Ph.D., Katsuhiro Suzuki, M.D., Thelma Tupasi, M.D., Won-Jung Koh, M.D., Barbara Seaworth, M.D., Lawrence J. Geiter, Ph.D., and Charles D. Wells, M.D.
N Engl J Med 2012;366:2151-60.

Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection
Maryline Bonnet, Manuela Pardini, Francesca Meacci, Germano Orru, Hasan Yesilkaya, Thierry Jarosz, Peter W. Andrew, Mike Barer, Francesco Checchi, Heinz Rinder, Graziella Orefici, Sabine Rüsch-Gerdes, Lanfranco Fattorini, Marco Rinaldo Oggioni, Juliet Melzer, Stefan Niemann, Francis Varaine
1 Clinical Research department, Epicentre, Geneva, Switzerland, 2 Dipartimento di Malattie Infettive Parassitarie e Immunomediate, Istituto Superiore di Sanita` , Rome, Italy, 3 Dipartimento di Biologia Molecolare, Universita` di Siena, Siena, Italy, 4 Dipartimento di Scienze Odontostomatologiche, Universita` di Cagliari, Cagliari, Italy, 5 Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, 6 Essai clinique Evaluation Epidemiologie Statistiques, Paris, France, 7 Sachgebiet Parasitologie Bayerisches, Landesamt fu¨ r Gesundheit und Lebensmittelsicherheit, Oberschleißheim, Germany, 8 National Reference Center for Mycobacteriology, Forschungszentrum Borstel, Borstel, Germany, 9 Medical department, Me´decins Sans Frontie`res, Paris, France
PLoS ONE | www.plosone.org
4 August 2011 | Volume 6 | Issue 8 | e23081

Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-a) era
Francesca Nacci, Marco Matucci-Cerinic 
Department of Rheumatology AVC, Medicine and Deno the Center University of Florence, Florence, Italy b Department of Biomedicine and Division Rheumatology AOUC, Medicine and Deno the Center University of Florence, Florence, Italy
Best Practice & Research Clinical Rheumatology 25 (2011) 375–388

Efficacy and Safety of Linezolid in the Treatment of Extensively Drug-Resistant Tuberculosis
Shen-Jie Tang1,2†, Qing Zhang1,2†, Lin-Hai Zeng1,2, Hua Sun1,2, Jin Gu1,2, Xiao-Hui Hao1,2, Yi-Dian Liu1,2, Lan Yao1,2, and He-Ping Xiao1,2* 1Tuberculosis Diagnosis and Treatment Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai; and 2Shanghai Key Laboratory of Tuberculosis, Shanghai, China
Jpn. J. Infect. Dis., 64, 509-512, 2011

Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling, M.D., M. Elsa Villarino, M.D., M.P.H., Andrey S. Borisov, M.D., M.P.H., Nong Shang, Ph.D., Fred Gordin, M.D., Erin Bliven-Sizemore, M.P.H., Judith Hackman, R.N., Carol Dukes Hamilton, M.D., Dick Menzies, M.D., Amy Kerrigan, R.N., M.S.N., Stephen E. Weis, D.O., Marc Weiner, M.D., Diane Wing, R.N., Marcus B. Conde, M.D., Lorna Bozeman, M.S., C. Robert Horsburgh, Jr., M.D., Richard E. Chaisson, M.D., for the TB Trials Consortium PREVENT TB Study Team*
N Engl J Med 2011;365:2155-66.

American Thoracic Society Documents
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
David E. Griffith, Timothy Aksamit, Barbara A. Brown-Elliott, Antonino Catanzaro, Charles Daley, Fred Gordin, Steven M. Holland, Robert Horsburgh, Gwen Huitt, Michael F. Iademarco, Michael Iseman, Kenneth Olivier, Stephen Ruoss, C. Fordham von Reyn, Richard J. Wallace, Jr., and Kevin Winthrop, on behalf of the ATS Mycobacterial Diseases Subcommittee
Am J Respir Crit Care Med Vol 175. pp 367–416, 2007
DOI: 10.1164/rccm.200604-571ST
Internet address: www.atsjournals.org